In order to determine the therapeutic efficacy of targeted and non-targeted liposomes containing CD73 siRNA in combination therapy with liposomal doxorubicin (Lipo Dox), several parameters including tumor growth and survival rate were monitored during 70 days post tumor inoculation. The gene discussed is NT5E; the disease is neoplasm.